Bosutinib (Phase 2 part) ( DrugBank: Bosutinib )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 1 |
2. Amyotrophic lateral sclerosis
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04744532 (ClinicalTrials.gov) | March 19, 2019 | 9/1/2021 | iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study | Phase 1/2 Study of Bosutinib in Patients With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | Drug: Bosutinib (Phase 1 part);Drug: Bosutinib (Phase 2 part) | Kyoto University | Tokushima University;Kitasato University;Tottori University;Nara Medical University;Toho University;Hiroshima University;Pfizer | Recruiting | 20 Years | 75 Years | All | 49 | Phase 1/Phase 2 | Japan |